{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:51:19Z","timestamp":1794567079204,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012453","name":"Providence Health Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A high proportion of people receiving both oral and injectable opioid agonist treatment report concurrent use of stimulants (i.e. cocaine and or amphetamines), which has been associated with higher rates of continued illicit opioid use and treatment dropout. A recent randomized controlled trial demonstrated the effectiveness of dextroamphetamine (a prescribed stimulant) at reducing craving for and use of cocaine among patients receiving injectable opioid agonist treatment. Following this evidence, dextroamphetamine has been prescribed to patients with stimulant use disorder at a clinic in Vancouver. This study investigates perceptions of the effectiveness of dextroamphetamine from the perspective of these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were collected using small focus groups and one-on-one interviews with patients who were currently or formerly receiving dextroamphetamine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920). Thematic analysis was conducted using an iterative approach, moving between data collection and analysis to search for patterns in the data across transcripts. This process led to the defining and naming of three central themes responding to the research question.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Participants reported a range of stimulant use types, including cocaine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), methamphetamine (n\u2009=\u20098), or both (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). Three central themes were identified as relating to participants\u2019 perceptions of the effectiveness of the medication: 1) achieving a substitution effect (i.e. extent to which dextroamphetamine provided a substitution for the effect they received from use of illicit stimulants); 2) Reaching a preferred dose (i.e. speed of titration and effect of the dose received); and 3) Ease of medication access (i.e. preference for take home doses (i.e. carries) vs. medication integrated into care at the clinic).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the context of continued investigation of pharmacological treatments for stimulant use disorder, the present study has highlighted how the study of clinical outcomes could be extended to account for factors that contribute to perceptions of effectiveness from the perspective of patients. In practice, elements of treatment delivery (e.g. dosing and dispensation protocols) can be adjusted to allow for various scenarios (e.g. on site vs. take home dosing) by which dextroamphetamine and other pharmacological stimulants could be implemented to provide \u201ceffective\u201d treatment for people with a wide range of treatment goals and needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13011-021-00399-2","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T08:02:53Z","timestamp":1631779373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder:\u00a0a qualitative study\u00a0with patients receiving injectable opioid agonist treatment"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-5717","authenticated-orcid":false,"given":"Heather","family":"Palis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald \u201c Spike\u201d","family":"Peachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Westfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bojanczyk-Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"issue":"5","key":"399_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447\u201355. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.0109.","journal-title":"JAMA Psychiatry"},{"key":"399_CR2","volume":"2","author":"M Ferri","year":"2005","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev. 2005;2:CD003410.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20133","key":"399_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.forsciint.2011.01.046","volume":"215","author":"EJ Cone","year":"2012","unstructured":"Cone EJ. Oral fluid results compared to self reports of recent cocaine and heroin use by methadone maintenance patients. Forensic Sci Int. 2012;215(1\u20133):88\u201391. https:\/\/doi.org\/10.1016\/j.forsciint.2011.01.046.","journal-title":"Forensic Sci Int"},{"issue":"2\u20133","key":"399_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.drugalcdep.2007.02.007","volume":"89","author":"JD Raffa","year":"2007","unstructured":"Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend. 2007;89(2\u20133):306\u20139. https:\/\/doi.org\/10.1016\/j.drugalcdep.2007.02.007.","journal-title":"Drug Alcohol Depend"},{"key":"399_CR5","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M et al: Characteristics and response to treatment among indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence. Drug Alcohol Rev 2017.","DOI":"10.1111\/dar.12573"},{"issue":"9697","key":"399_CR6","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0140-6736(09)61420-3","volume":"374","author":"J Marsden","year":"2009","unstructured":"Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet. 2009;374(9697):1262\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(09)61420-3.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"399_CR7","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0924-977X(10)70001-8","volume":"20","author":"P Blanken","year":"2010","unstructured":"Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, et al. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol. 2010;20(Suppl 2):S105\u201358. https:\/\/doi.org\/10.1016\/S0924-977X(10)70001-8.","journal-title":"Eur Neuropsychopharmacol"},{"key":"399_CR8","volume":"9","author":"X Castells","year":"2016","unstructured":"Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:CD007380.","journal-title":"Cochrane Database Syst Rev"},{"key":"399_CR9","volume":"9","author":"C Perez-Mana","year":"2013","unstructured":"Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013;9:CD009695.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10034","key":"399_CR10","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(16)00205-1","volume":"387","author":"M Nuijten","year":"2016","unstructured":"Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10034):2226\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(16)00205-1.","journal-title":"Lancet"},{"key":"399_CR11","doi-asserted-by":"crossref","unstructured":"Blanken P, Nuijten M, van den Brink W, Hendriks VM: Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial. Addiction 2019.","DOI":"10.1111\/add.14874"},{"issue":"4","key":"399_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs. 2020;34(4):337\u201365. https:\/\/doi.org\/10.1007\/s40263-020-00711-x.","journal-title":"CNS Drugs"},{"key":"399_CR13","doi-asserted-by":"crossref","unstructured":"Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM: Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. In: Psychopharmacology (Berl). Volume 237, edn. Germany; 2020: 2233\u20132255.","DOI":"10.1007\/s00213-020-05563-3"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2019.03.012","volume":"101","author":"EPH Oviedo-Joekes","year":"2019","unstructured":"Oviedo-Joekes EPH, Guh D, Marchand K, Brissette SH, MacDonald S, Lock K, et al. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. J Subst Abus Treat. 2019;101:50\u20134. https:\/\/doi.org\/10.1016\/j.jsat.2019.03.012.","journal-title":"J Subst Abus Treat"},{"key":"399_CR15","unstructured":"Creswell JW: Research design: qualitative, quantitative, and mixed methods approaches; 2012."},{"issue":"2","key":"399_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"7","key":"399_CR17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/dar.13117","volume":"39","author":"H Palis","year":"2020","unstructured":"Palis H, Harrison S, MacDonald S, Marsh DC, Schechter MT, Oviedo-Joekes E. Self-managing illicit stimulant use: a qualitative study with patients receiving injectable opioid agonist treatment. Drug Alcohol Rev. 2020;39(7):914\u201323. https:\/\/doi.org\/10.1111\/dar.13117.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"399_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13011-017-0110-9","volume":"12","author":"H Palis","year":"2017","unstructured":"Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, et al. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. Subst Abuse Treat Prev Policy. 2017;12(1):25. https:\/\/doi.org\/10.1186\/s13011-017-0110-9.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"399_CR19","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, Marchand K, Palis H, Guh D, Brissette S, Lock K, et al. Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder. In Addiction Research & Theory. 2016:1\u201310.","DOI":"10.1080\/16066359.2016.1263729"},{"key":"399_CR20","unstructured":"N'Vivo. In., Version 12 edn; 2018."},{"issue":"6","key":"399_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","volume":"72","author":"FR Levin","year":"2015","unstructured":"Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(6):593\u2013602. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.41.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"399_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1152","volume":"1","author":"YJ Wei","year":"2018","unstructured":"Wei YJ, Zhu Y, Liu W, Bussing R, Winterstein AG. Prevalence of and factors associated with long-term concurrent use of stimulants and opioids among adults with attention-deficit\/hyperactivity disorder. JAMA Netw Open. 2018;1(4):e181152. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.1152.","journal-title":"JAMA Netw Open"},{"key":"399_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2013.09.026","volume":"134","author":"G van de Glind","year":"2014","unstructured":"van de Glind G, Konstenius M, Koeter MWJ, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, et al. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend. 2014;134:158\u201366. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.09.026.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"399_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1046\/j.1360-0443.2003.00447.x","volume":"98","author":"J Shearer","year":"2003","unstructured":"Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction. 2003;98(8):1137\u201341. https:\/\/doi.org\/10.1046\/j.1360-0443.2003.00447.x.","journal-title":"Addiction"},{"issue":"9","key":"399_CR25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1046\/j.1360-0443.2001.96912898.x","volume":"96","author":"J Shearer","year":"2001","unstructured":"Shearer J, Wodak A, Mattick RP, Van Beek I, Lewis J, Hall W, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction. 2001;96(9):1289\u201396. https:\/\/doi.org\/10.1046\/j.1360-0443.2001.96912898.x.","journal-title":"Addiction"},{"key":"399_CR26","unstructured":"United Nations Office on Drugs and Crime: World Drug Report: Stimulants. In.; 2019."},{"issue":"6","key":"399_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/ADM.0000000000000631","volume":"14","author":"H Palis","year":"2020","unstructured":"Palis H, Marchand K, Beaumont S, Guh D, Harrison S, MacDonald S, et al. Physician communication in injectable opioid agonist treatment: collecting patient ratings with the communication assessment tool. J Addict Med. 2020;14(6):480\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000631.","journal-title":"J Addict Med"},{"issue":"1","key":"399_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7. https:\/\/doi.org\/10.1186\/s13011-020-0253-y.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"399_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/ADM.0000000000000507","volume":"13","author":"P Hemmons","year":"2019","unstructured":"Hemmons P, Bach P, Colizza K, Nolan S. Initiation and rapid titration of methadone in an acute care setting for the treatment of opioid use disorder: a case report. J Addict Med. 2019;13(5):408\u201311. https:\/\/doi.org\/10.1097\/ADM.0000000000000507.","journal-title":"J Addict Med"},{"key":"399_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fpsyt.2012.00077","volume":"3","author":"JM Schmitz","year":"2012","unstructured":"Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of Modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry. 2012;3:77.","journal-title":"Front Psychiatry"},{"key":"399_CR31","doi-asserted-by":"crossref","unstructured":"Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM: Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. In: Addiction. Volume 105, edn. England; 2010: 146\u2013154.","DOI":"10.1111\/j.1360-0443.2009.02717.x"},{"issue":"5","key":"399_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.pec.2016.12.001","volume":"100","author":"J Trujols","year":"2017","unstructured":"Trujols J, Gonzalez-Saiz F, Manresa MJ, Alcaraz S, Batlle F, Duran-Sindreu S, et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 2017;100(5):981\u20136. https:\/\/doi.org\/10.1016\/j.pec.2016.12.001.","journal-title":"Patient Educ Couns"},{"key":"399_CR33","doi-asserted-by":"crossref","unstructured":"Palis H, Guh D, MacDonald S, Harrison S, Brissette S, Marsh DC, Schechter MT, Oviedo-Joekes E: Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach. In: Drug Alcohol Depend. Volume 218, edn. Ireland: \u00a9 2020 Elsevier B.V; 2021: 108333.","DOI":"10.1016\/j.drugalcdep.2020.108333"},{"key":"399_CR34","unstructured":"European Monitoring Centre on Drugs and Drug Addiction: Strategies to prevent diversion of opioid substitution treatment medications In.; 2016."},{"key":"399_CR35","unstructured":"Council SF: The Federal Council adapts the criteria for the delivery of medical heroin In.; 2020."},{"key":"399_CR36","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, K. H: Take Home Injectable Opioids for Opioid Use Disorder During and After the COVID-19 Pandemic Is in Urgent Need: A Case Study. Research Square (Pre-print) 2021.","DOI":"10.21203\/rs.3.rs-136113\/v1"},{"issue":"1","key":"399_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37. https:\/\/doi.org\/10.1186\/s13011-019-0227-0.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"399_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):1\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"399_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/nur.20259","volume":"31","author":"G Novick","year":"2008","unstructured":"Novick G. Is there a bias against telephone interviews in qualitative research? Res Nurs Health. 2008;31(4):391\u20138. https:\/\/doi.org\/10.1002\/nur.20259.","journal-title":"Res Nurs Health"},{"issue":"3","key":"399_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","volume":"51","author":"S Darke","year":"1998","unstructured":"Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253\u201363; discussion 267-258. https:\/\/doi.org\/10.1016\/S0376-8716(98)00028-3.","journal-title":"Drug Alcohol Depend"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-021-00399-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T08:40:56Z","timestamp":1631781656000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-021-00399-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s13011-021-00399-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"3 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was provided by the University of British Columbia\/Providence Health Care Behavioural Research Ethics Board (H19\u201302514). Participants provided written informed consent prior to beginning data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual details or data are presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}